KEGG   DRUG: Brivaracetam
Entry
D08879                      Drug                                   
Name
Brivaracetam (JAN/USAN/INN);
Briviact (TN)
Product
BRIVIACT (UCB)
Formula
C11H20N2O2
Exact mass
212.1525
Mol weight
212.29
Structure
Class
Neuropsychiatric agent
 DG03199  Antiepileptic agent
  DG02038  Piracetam antiepileptic
Metabolizing enzyme substrate
 DG01639  CYP2C19 substrate
Remark
Therapeutic category: 1139
ATC code: N03AX23
Product: D08879<JP/US>
Efficacy
Anticonvulsant, Pain relief
Comment
Levetiracetam [DR:D00709] derivative
Treatment of epilepsy, neuropathic pain and essential tremor
Target
SV2A [HSA:9900] [KO:K06258]
  Pathway
hsa04512  ECM-receptor interaction
Metabolism
Enzyme: CYP2C19 [HSA:1557]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 N NERVOUS SYSTEM
  N03 ANTIEPILEPTICS
   N03A ANTIEPILEPTICS
    N03AX Other antiepileptics
     N03AX23 Brivaracetam
      D08879  Brivaracetam (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Anticonvulsants
  Anticonvulsants, Other
   Brivaracetam
    D08879  Brivaracetam (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   113  Antiepileptics
    1139  Others
     D08879  Brivaracetam (JAN/USAN/INN)
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG03199  Antiepileptic agent
   DG02038  Piracetam antiepileptic
    D08879  Brivaracetam
 Metabolizing enzyme substrate
  DG01639  CYP2C19 substrate
   D08879  Brivaracetam
Drug classes [BR:br08332]
 Neuropsychiatric agent
  DG03199  Antiepileptic agent
   D08879  Brivaracetam
Target-based classification of drugs [BR:br08310]
 Transporters
  Major facilitator superfamily
   VNT family
    SV2A
     D08879  Brivaracetam (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D08879
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08879
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D08879
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D08879
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D08879
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D08879
Other DBs
CAS: 357336-20-0
PubChem: 96025562
ChEBI: 133013
PDB-CCD: VLX[PDBj]
LigandBox: D08879
LinkDB
KCF data

ATOM        15
            1   N1y N    29.4350  -21.8855
            2   C1c C    30.6233  -21.1865
            3   C5x C    28.2467  -21.0467
            4   C1x C    28.9457  -23.2136
            5   C5a C    31.8117  -21.8855
            6   C1x C    27.1283  -21.8855
            7   O5x O    28.2467  -19.6487
            8   C1y C    27.5477  -23.2136
            9   N1a N    33.0000  -21.1865
            10  O5a O    31.8117  -23.2835
            11  C1b C    26.7213  -24.3412
            12  C1b C    25.3184  -24.1880
            13  C1a C    24.4873  -25.3220
            14  C1b C    30.6233  -19.7885
            15  C1a C    31.8340  -19.0895
BOND        15
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     3   6 1
            6     3   7 2
            7     4   8 1
            8     5   9 1
            9     5  10 2
            10    6   8 1
            11    8  11 1 #Down
            12   11  12 1
            13   12  13 1
            14    2  14 1 #Up
            15   14  15 1

» Japanese version   » Back

DBGET integrated database retrieval system